Atlas Trials

Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT

Clinical trial NCT02267915 · UNKNOWN

Trial details

NCT number
NCT02267915
Sponsor
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Mantle-cell Lymphoma
Start date
2015-03-01
Primary completion
2019-12-01
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.